HRP20220335T1 - Rani i neinvazivni postupak za procjenu rizika kod nekog subjekta od obolijevanja od duktalnog adenokarcinoma gušterače i postupci za liječenje takve bolesti - Google Patents
Rani i neinvazivni postupak za procjenu rizika kod nekog subjekta od obolijevanja od duktalnog adenokarcinoma gušterače i postupci za liječenje takve bolesti Download PDFInfo
- Publication number
- HRP20220335T1 HRP20220335T1 HRP20220335TT HRP20220335T HRP20220335T1 HR P20220335 T1 HRP20220335 T1 HR P20220335T1 HR P20220335T T HRP20220335T T HR P20220335TT HR P20220335 T HRP20220335 T HR P20220335T HR P20220335 T1 HRP20220335 T1 HR P20220335T1
- Authority
- HR
- Croatia
- Prior art keywords
- βig
- ductal adenocarcinoma
- level
- therapy
- subject
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305276 | 2016-03-15 | ||
| EP17710554.1A EP3430404B1 (en) | 2016-03-15 | 2017-03-15 | Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease |
| PCT/EP2017/056150 WO2017158043A1 (en) | 2016-03-15 | 2017-03-15 | Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220335T1 true HRP20220335T1 (hr) | 2022-05-13 |
Family
ID=55588194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220335TT HRP20220335T1 (hr) | 2016-03-15 | 2017-03-15 | Rani i neinvazivni postupak za procjenu rizika kod nekog subjekta od obolijevanja od duktalnog adenokarcinoma gušterače i postupci za liječenje takve bolesti |
| HRP20230391TT HRP20230391T1 (hr) | 2016-03-15 | 2017-03-15 | Postupak za aktiviranje antitumorskog odgovora cd8+t stanica kod pacijenta oboljelog od raka |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230391TT HRP20230391T1 (hr) | 2016-03-15 | 2017-03-15 | Postupak za aktiviranje antitumorskog odgovora cd8+t stanica kod pacijenta oboljelog od raka |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11740243B2 (enExample) |
| EP (2) | EP3430404B1 (enExample) |
| JP (3) | JP6903680B2 (enExample) |
| KR (2) | KR102402444B1 (enExample) |
| DK (2) | DK3430404T3 (enExample) |
| ES (2) | ES2911038T3 (enExample) |
| FI (1) | FI3779447T3 (enExample) |
| HR (2) | HRP20220335T1 (enExample) |
| PL (2) | PL3779447T3 (enExample) |
| WO (1) | WO2017158043A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3779447T3 (pl) * | 2016-03-15 | 2023-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Sposób aktywowania przeciwnowotworowej odpowiedzi komórek t cd8+ u pacjenta dotknego nowotworem |
| CN112955462B (zh) * | 2018-10-18 | 2024-05-07 | 国家医疗保健研究所 | 用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合 |
| KR102169346B1 (ko) * | 2019-03-27 | 2020-10-23 | 덕성여자대학교 산학협력단 | 이종이식 동물 모델의 제조방법 및 이종이식 성공 여부 판별 방법 |
| CN118076633A (zh) | 2021-07-29 | 2024-05-24 | 法国国家健康与医学研究院 | 人源化抗-人βig-h3蛋白及其用途 |
| WO2025068157A1 (en) * | 2023-09-25 | 2025-04-03 | Stromacare | COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER |
| WO2025224297A1 (en) * | 2024-04-26 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to tgfbi and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| US20050164197A1 (en) * | 2002-04-19 | 2005-07-28 | In-San Kim | Method for measuring the amount of betaig-h3 protein and diagnostic kit using the same |
| KR20060056445A (ko) | 2004-11-19 | 2006-05-24 | 주식회사 리젠 바이오텍 | 인간 βｉｇ－ｈ３에 대한 단클론 항체 |
| ITVI20050059A1 (it) * | 2005-03-04 | 2006-09-05 | Consorzio Per Gli Studi Universitari In Verona | Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali |
| EP2463657A1 (en) * | 2010-12-13 | 2012-06-13 | Université de Liège | Biomarkers, uses of biomarkers and a method of identifying biomarkers |
| JP2014507160A (ja) * | 2011-02-22 | 2014-03-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 循環バイオマーカー |
| US9845471B2 (en) * | 2013-01-15 | 2017-12-19 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating pancreatic cancer |
| KR101515700B1 (ko) | 2013-05-15 | 2015-04-27 | 경북대학교 산학협력단 | Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법 |
| WO2015200790A2 (en) | 2014-06-26 | 2015-12-30 | Yale University | Compositions and methods to regulate renalase in the treatment of diseases and disorders |
| ES2820768T3 (es) | 2015-04-03 | 2021-04-22 | Xoma Technology Ltd | Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1 |
| PL3779447T3 (pl) * | 2016-03-15 | 2023-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Sposób aktywowania przeciwnowotworowej odpowiedzi komórek t cd8+ u pacjenta dotknego nowotworem |
| KR102082344B1 (ko) * | 2018-06-21 | 2020-02-27 | 조성은 | 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 용도 |
-
2017
- 2017-03-15 PL PL20195759.4T patent/PL3779447T3/pl unknown
- 2017-03-15 PL PL17710554T patent/PL3430404T3/pl unknown
- 2017-03-15 KR KR1020187027907A patent/KR102402444B1/ko active Active
- 2017-03-15 US US16/081,462 patent/US11740243B2/en active Active
- 2017-03-15 WO PCT/EP2017/056150 patent/WO2017158043A1/en not_active Ceased
- 2017-03-15 ES ES17710554T patent/ES2911038T3/es active Active
- 2017-03-15 HR HRP20220335TT patent/HRP20220335T1/hr unknown
- 2017-03-15 DK DK17710554.1T patent/DK3430404T3/da active
- 2017-03-15 HR HRP20230391TT patent/HRP20230391T1/hr unknown
- 2017-03-15 FI FIEP20195759.4T patent/FI3779447T3/fi not_active Application Discontinuation
- 2017-03-15 KR KR1020217014527A patent/KR102408161B1/ko active Active
- 2017-03-15 EP EP17710554.1A patent/EP3430404B1/en active Active
- 2017-03-15 ES ES20195759T patent/ES2944259T3/es active Active
- 2017-03-15 JP JP2018548412A patent/JP6903680B2/ja active Active
- 2017-03-15 DK DK20195759.4T patent/DK3779447T3/da active
- 2017-03-15 EP EP20195759.4A patent/EP3779447B1/en active Active
-
2021
- 2021-04-12 JP JP2021067346A patent/JP7569741B2/ja active Active
-
2023
- 2023-01-12 JP JP2023003171A patent/JP2023052360A/ja active Pending
- 2023-07-07 US US18/348,398 patent/US12140594B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3779447A1 (en) | 2021-02-17 |
| KR102408161B1 (ko) | 2022-06-13 |
| FI3779447T3 (fi) | 2023-04-21 |
| WO2017158043A1 (en) | 2017-09-21 |
| EP3430404A1 (en) | 2019-01-23 |
| US12140594B2 (en) | 2024-11-12 |
| DK3430404T3 (da) | 2022-03-21 |
| DK3779447T3 (da) | 2023-04-24 |
| EP3430404B1 (en) | 2022-01-05 |
| JP2023052360A (ja) | 2023-04-11 |
| KR102402444B1 (ko) | 2022-05-27 |
| KR20180120716A (ko) | 2018-11-06 |
| HRP20230391T1 (hr) | 2023-07-07 |
| KR20210059020A (ko) | 2021-05-24 |
| PL3779447T3 (pl) | 2023-06-26 |
| US20240159759A1 (en) | 2024-05-16 |
| US11740243B2 (en) | 2023-08-29 |
| US20190086417A1 (en) | 2019-03-21 |
| EP3779447B1 (en) | 2023-02-08 |
| JP7569741B2 (ja) | 2024-10-18 |
| ES2944259T3 (es) | 2023-06-20 |
| JP2019512695A (ja) | 2019-05-16 |
| ES2911038T3 (es) | 2022-05-17 |
| JP2021119146A (ja) | 2021-08-12 |
| PL3430404T3 (pl) | 2022-05-02 |
| JP6903680B2 (ja) | 2021-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pigna et al. | Aerobic exercise and pharmacological treatments counteract cachexia by modulating autophagy in colon cancer | |
| MY200300A (en) | Methods for determining dpp3 and therapeutic methods | |
| MX392671B (es) | Antagonistas de unión a pd-l1 y usos de los mismos para el tratamiento de cáncer | |
| MX2020009991A (es) | Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer. | |
| EA201391587A1 (ru) | Комбинированная терапия на основе hsp90 | |
| MA52251A (fr) | Procédés et systèmes de sélection et de traitement de patients souffrant de maladies inflammatoires | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| JP2019512695A5 (enExample) | ||
| CL2020003204A1 (es) | Tratamiento de nsclc en etapa iii y mitigación de condiciones patológicas asociadas al tratamiento | |
| BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
| MY209272A (en) | Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors | |
| WO2018022604A3 (en) | Methods of diagnosing and treating alzheimer's disease with s-equol | |
| EA201891693A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови | |
| FI3452829T3 (fi) | Perm endometriumsyövän markkerina | |
| Rachner et al. | P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer | |
| Pellegrini et al. | Measuring the impact of intensity of treatment using RDD and covariates: the case of Structural Funds | |
| BR112019006422A2 (pt) | anticorpo monoclonal contra fzd10 e utilização do mesmo | |
| ES2481517R1 (es) | Método para el diagnóstico de la enfermedad de parkinson en estadios tempranos | |
| Dimitrova et al. | Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value in predicting outcomes of colon liver metastases and that value's association with Beclin-1 expression | |
| ATE529750T1 (de) | Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target | |
| Wakerley et al. | Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: search for a biomarker | |
| Dancey | Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials? | |
| Peled et al. | P3. 01-056 Intracranial Activity of Osimertinib in Naïve EGFRm T790M (-) And Treated EGFRm T790M (+) NSCLC Patients with Asymptomatic Brain Metastases | |
| UA117184C2 (uk) | Спосіб визначення розповсюдженості злоякісних пухлин ободової кишки | |
| Lutgens et al. | Different risk factors for colitis associated colorectal cancer in ulcerative colitis and Crohn's disease |